Abstract
Serum bone Gla protein (BGP) and bone alkaline phosphatase (B-AP), markers of bone formation, carboxyterminal cross-linked telopeptide of type I collagen (ICTP), marker of bone resorption, and aminoterminal propeptide of type III procollagen (PIIINP) levels, index of collagen synthesis, were determined in 8 adults (mean age±SE: 29.6±1.2 yr) with childhood onset GHD before and after 3 and 6 months of recombinant GH treatment (0.5 IU/kg/week). Before treatment, mean BGP (3.8±.5 ng/ml) and B-AP (44.9±6.9 IU/L) were significantly (p<0.001 and p<0.05, respectively) lower than those recorded in normals (5.4±0.1 ng/ml and 61.8+1.9 IU/L, respectively), while serum ICTP and PIIINP levels were similar to those found in controls (ICTP: 4.7±0.8 vs 4.1±0.3 ng/ml; PIIINP: 3.7±0.6 vs 3.2±0.2 ng/ml). BGP and ICTP levels significantly (p<0.005) increased after 3 (28.4±5.3 ng/ml and 17.5±2.8 ng/ml, respectively) and 6 months (25.1±5.0 ng/ml and 15.0±1.9 ng/ml, respectively) of recombinant GH treatment. B-AP levels significantly (p<0.01) increased during the treatment (basal: 44.9±6.9 IU/L, 3rd month: 173.6±40 IU/L, 6th month: 194.4±40 IU/L), while non B-AP levels remained similar to those recorded in basal condition. Serum PIIINP levels significantly (p<0.0001) rose up after 3 (12.5±1.4 ng/ml) and 6 months (10.2±0.8 ng/ml). Serum BGP and ICTP levels were directly (r=0.85, p<0.001; r=0.53, p<0.01) correlated with serum IGF-I levels. In conclusion, our study show that in adulthood GH deficiency seems to exert less relevant negative effects on bone and collagen turnover than those previously observed in childhood. Furthermore, GH treatment is able to reactivate the bone remodeling of adults with GH deficiency, probably through a local mediation of IGF-I. The long term effect of GH on bone mineral content remains to be established, since recombinant GH treatment increases both bone formation and bone resorption.
Similar content being viewed by others
References
Bouillon R. Growth hormone and bone. Horm. Res. 36: 49, 1991.
Frost H.M. Tetracycline-based histological analysis of bone remodelling. Calcif. Tissue Res. 3: 211, 1969.
Parfitt A.M. Bone remodelling: relationship to the amount and structure of bone and the pathogenesis and prevention of fracture. In: Riggs B.L., Melton III L.J. (Eds.), Osteoporosis: Etiology, Diagnosis and Management. Raven Press, New York, 1988, p. 45.
Parfitt A.M. Growth hormone and adult bone remodeling. Clin. Endocrinol. (Oxf.) 35: 467, 1991.
Ernst M., Froesch E.R. Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor I. Biochem. Biophys. Res. Commun. 151: 142, 1988.
Brixen K., Nielsen H.K., Mosekilde L, Flyvbjerg A. A short course of recombinant human growth hormone treatment stimulates osteoblast and activates bone remodelling in normal human volunteers. J. Bone Min. Res. 5: 609, 1990.
Ferrandez A., Zachmann M, Prader A., Illig R. Isolated growth hormone deficiency in prepubertal children: influence of human growth hormone on longitudinal growth, adipose tissue, bone mass and bone maturation. Helv. Paediatr. Acta. 6: 566, 1970.
Shore R.M., Chesney R.W., Mazess R.B., Rose P.G., Bargman G.J. Bone mineral status in growth hormone deficiency. J. Pediatr. 96: 393, 1980.
Johansen J.S., Giwercman A., Hartwell D., Nielsen C.T., Price P.A., Christiansen C., Skakkebaek N.E. Serum bone-GLA protein as a marker of bone growth in children and adolescents: correlation with age, height, serum insulin-like growth factor I and serum testosterone. J. Clin. Endocrinol. Metab. 67: 273, 1988.
Johansen J.S., Jensen S.B., Riis B.J., Rasmussen L., Zachmann M., Christiansen C. Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy. J. Clin. Endocrinol. Metab. 71: 122, 1990.
Sartorio A., Conti A., Guzzaloni G., Faglia G. Serum osteocalcin levels in patients with GH deficiency before and during GH treatment. Acta Paediatr. Scand. 80: 100, 1991.
Black M.M., Shuster S., Bottoms E. Skin collagen and thickness in acromegaly and hypopituitarism. Clin. Endocrinol. (Oxf.) 1: 259, 1972.
Sartorio A., Conti A., Morabito F., Monzani M., FagliaZ G. Serum bone Gla protein and aminoterminal propeptide of type III procollagen levels in patients with GH deficiency before and after met-GH treatment. In: Cavallo L., Job J.C., New M.I. (Eds.), Growth disorders: the state of the art. Serono Symposia, Raven Press, New York, 81: 329, 1991.
Saggese G., Baroncelli G.I., Bertelloni S. Phospho-calcium metabolism and related parameters: relationship with growth. In: Cavallo L., Job J.C., New M.I. (Eds.), Growth disorders: the state of the art. Serono Symposia, Raven Press, New York, 81: 137, 1991.
Johansen J.S., Pedersen S.A., Jorgensen J.O.L., Riis B.J., Christiansen C., Christiansen J.S., Skakkebaek N.E. Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults. J. Clin. Endocrinol. Metab. 70: 916, 1990.
Kaufman J.M., Taelman P., Vermeulen A., Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J. Clin. Endocrinol. Metab. 74: 118, 1992.
Whitehead H.M., Boream C., Mcllrath E.M., Sheridan B., Kennedy L., Atkinson A.B., Hadden D.R. Growth hormone treatment of adults with growth hormone deficiency: results of 13-month placebo controlled cross-over study. Clin. Endocrinol. (Oxf.) 36: 45, 1992.
Cuneo R.C., Salomon F., McGauley G.A., Sonksen P.H. The growth hormone deficiency syndrome in adults. Clin. Endocrinol. (Oxf.) 37: 387, 1992.
Rosalki S.B., Foo A.Y. Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clin. Chem. 30: 1182, 1984.
Raisz L.G. Local and systemic factors in the pathogenesis of osteoporosis. N. Engl. J. Med. 328: 818, 1988.
Hock J.M., Centrella M., Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 122: 254, 1988.
Jensen L.T., Jorgensen J.O.L., Risteli J., Christiansen J.S., Lorenzen I. Type I and III procollagen propeptide in growth hormone-deficient patients: effects of increasing doses of GH. Acta Endocrinol. (Copenh.) 124: 278, 1991.
Elomaa I., Virkkunen P., Risteli L., Risteli J. Serum concentration of the cross-linked carboxiterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br. J. Cancer 6: 337, 1992.
Risteli J., Niemi S., Elomaa I., Risteli L. Bone resorption assay based on a peptide liberated during type I degradation. J. Bone Min. Res. 6 (Suppl 1): 251, 1991.
Elomaa I., Virkkunen P., Risteli L., Risteli J. A new sensitive bone resorption marker in serum. A cross-linked peptide liberated during type I collagen degradation. Preliminary results in multiple myeloma. Bone Miner. 17 (Suppl 1): 134, 1992.
Sartorio A., Conti A., Monzani M., Faglia G. Serum bone Gla protein (BGP) and carboxyterminal cross linked telopeptide of type I collagen (ICTP) levels in patients with primary hyperparathyroidism before and after surgery. Eur. J. Int. Med., in press.
Van der Veen E.A., Netelembos J.C. Growth hormone (replacement) therapy in adults: bone and calcium metabolism. Horm. Res. 33 (Suppl. 4): 65, 1990.
Bengtsson B.A., Eden S., Lonn L., Kvist H., Stokland A., Lindstedt G., Bosaeus I, Tolli J., Sjostrom L., Isaksson O.G.P. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76: 309, 1993.
Sartorio A., Conti A., Monzani M. New markers of bone and collagen turnover in children and adults with GH deficiency. Postgrad. Med. J., in press.
Author information
Authors and Affiliations
Additional information
Partially supported by Progetti di Ricerca Corrente, Centro Auxologico Italiano, IRCCS, Milan, Italy.
Rights and permissions
About this article
Cite this article
Sartorio, A., Conti, A., Monzani, M. et al. Growth hormone treatment in adults with GH deficiency: Effects on new biochemical markers of bone and collagen turnover. J Endocrinol Invest 16, 893–898 (1993). https://doi.org/10.1007/BF03348952
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348952